A systematic review evaluating the effectiveness of nuclear medicine techniques in enhancing the diagnostic accuracy of stereotactic brain biopsies
- PMID: 40593338
- DOI: 10.1007/s10143-025-03698-5
A systematic review evaluating the effectiveness of nuclear medicine techniques in enhancing the diagnostic accuracy of stereotactic brain biopsies
Abstract
Purpose: The aim of the present systematic review is to assess the effectiveness of nuclear medicine methods to improve the diagnostic accuracy of stereotactic brain biopsies (SBB).
Methods: A search in Medline, Cochrane, and Scopus databases until 22nd August 2024 was performed to retrieve relevant studies, aided by a manual search in Google Scholar. After applying predetermined inclusion and exclusion criteria, a data extraction was performed. The risk of bias and concerns regarding applicability were evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.
Results: Thirteen studies (9 prospective and 4 retrospective) with a total of 337 patients were included in this systematic review. There was a high risk of bias at least in one domain in all studies, while in 4 studies there were high concerns regarding applicability at least in one domain. Positron emission tomography (PET) was used in 12 studies and single photon emission computed tomography (SPECT) in 1 study to design the trajectories of the biopsies. A diagnosis was established through SBB in 282 out of 291 patients, while for the remaining 46 patients there was no relevant data in the studies. Two studies provided data on sensitivity (76 - 81.2 %), specificity (50 - 80 %), and Area Under the Curve (AUC) (56.2 - 89 %).
Conclusion: Nuclear medicine has the potential to increase the diagnostic accuracy of SBB by improving targeting precision. Among the radiotracers, 11C-methionine emerged as the most effective, providing superior visualization of the metabolic active region of a brain tumor.
Keywords: Diagnostic accuracy; Nuclear medicine; Positron emission tomography; Single photon emission computed tomography; Stereotactic brain biopsies.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Data availability: No datasets were generated or analysed during the current study. Ethics approval: Not applicable (review article) Consent to participate: Not applicable Human ethics and consent to participate declarations: Not applicable
Similar articles
-
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.Health Technol Assess. 2011 Jan;15(4):iii-iv, 1-134. doi: 10.3310/hta15040. Health Technol Assess. 2011. PMID: 21276372 Free PMC article.
-
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884. Cochrane Database Syst Rev. 2017. PMID: 29164602 Free PMC article.
-
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2. Cochrane Database Syst Rev. 2017. PMID: 29164603 Free PMC article.
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
-
- Reitsma JB, Rutjes AW, Whiting P, Yang B, Leeflang MM, Bossuyt PM et al (2023) Assessing risk of bias and applicability. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (eds) Cochrane Handb Syst Rev Diagn Test Accuracy [Internet], 1st edn. Wiley, pp 169–201 [cited 2024 Mar 19]. Available from: https://onlinelibrary.wiley.com/doi/10.1002/9781119756194.ch8 - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical